Jan 30, 2020 - Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Jan 31, 2020 - AMGN earnings call for the period ending December 31, 2019.
Jan 30, 2020 - Q4 GDP hit the tape ahead of today's opening bell, with results better than analysts had been predicting: +2.1% was 30 basis points higher than the 1.8% expected.
Jan 30, 2020 - Economic Data Deluge
Jan 30, 2020 - Expectations for Q4 earnings were on the low side, both at Zacks and on the street, so take this giant bottom-line beat with a grain of salt.
Jan 31, 2020 - Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.
Feb 04, 2020 - Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
Feb 05, 2020 - Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Feb 11, 2020 - Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Feb 11, 2020 - J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.